Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof
AssigneeThe Doshisha
InventorsNoriko Koizumi, Naoki Okumura
Life of this patent
Estimating the term…
Abstract
Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
Claims20
A method for treating a corneal endothelial condition, disorder, or disease due to a transforming growth factor-β (TGF-β) signal in corneal endothelial cells in a subject, comprising administering an effective amount of a caspase inhibitor to the subject.
A method for treating a corneal endothelial condition, disorder, or disease due to overexpression of extracellular matrix in corneal endothelial cells in a subject, comprising administering an effective amount of a caspase inhibitor to the subject.
A method for treating a corneal endothelial condition, disorder, or disease due to a TGF-β signal, and overexpression of extracellular matrix in corneal endothelial cells in a subject, comprising administering a caspase inhibitor to the subject.
Dependencies are inferred from the claim text.